First Time Loading...

G1 Therapeutics Inc
NASDAQ:GTHX

Watchlist Manager
G1 Therapeutics Inc Logo
G1 Therapeutics Inc
NASDAQ:GTHX
Watchlist
Price: 4.11 USD -1.44% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

GTHX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. [ Read More ]

The intrinsic value of one GTHX stock under the Base Case scenario is 14.86 USD. Compared to the current market price of 4.11 USD, G1 Therapeutics Inc is Undervalued by 72%.

Key Points:
GTHX Intrinsic Value
Base Case
14.86 USD
Undervaluation 72%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
G1 Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GTHX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
G1 Therapeutics Inc

Provide an overview of the primary business activities
of G1 Therapeutics Inc.

What unique competitive advantages
does G1 Therapeutics Inc hold over its rivals?

What risks and challenges
does G1 Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in G1 Therapeutics Inc recently?

Summarize the latest earnings call
of G1 Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for G1 Therapeutics Inc.

Provide P/S
for G1 Therapeutics Inc.

Provide P/E
for G1 Therapeutics Inc.

Provide P/OCF
for G1 Therapeutics Inc.

Provide P/FCFE
for G1 Therapeutics Inc.

Provide P/B
for G1 Therapeutics Inc.

Provide EV/S
for G1 Therapeutics Inc.

Provide EV/GP
for G1 Therapeutics Inc.

Provide EV/EBITDA
for G1 Therapeutics Inc.

Provide EV/EBIT
for G1 Therapeutics Inc.

Provide EV/OCF
for G1 Therapeutics Inc.

Provide EV/FCFF
for G1 Therapeutics Inc.

Provide EV/IC
for G1 Therapeutics Inc.

Show me price targets
for G1 Therapeutics Inc made by professional analysts.

What are the Revenue projections
for G1 Therapeutics Inc?

How accurate were the past Revenue estimates
for G1 Therapeutics Inc?

What are the Net Income projections
for G1 Therapeutics Inc?

How accurate were the past Net Income estimates
for G1 Therapeutics Inc?

What are the EPS projections
for G1 Therapeutics Inc?

How accurate were the past EPS estimates
for G1 Therapeutics Inc?

What are the EBIT projections
for G1 Therapeutics Inc?

How accurate were the past EBIT estimates
for G1 Therapeutics Inc?

Compare the revenue forecasts
for G1 Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of G1 Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of G1 Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of G1 Therapeutics Inc compared to its peers.

Compare the P/E ratios
of G1 Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing G1 Therapeutics Inc with its peers.

Analyze the financial leverage
of G1 Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for G1 Therapeutics Inc.

Provide ROE
for G1 Therapeutics Inc.

Provide ROA
for G1 Therapeutics Inc.

Provide ROIC
for G1 Therapeutics Inc.

Provide ROCE
for G1 Therapeutics Inc.

Provide Gross Margin
for G1 Therapeutics Inc.

Provide Operating Margin
for G1 Therapeutics Inc.

Provide Net Margin
for G1 Therapeutics Inc.

Provide FCF Margin
for G1 Therapeutics Inc.

Show all solvency ratios
for G1 Therapeutics Inc.

Provide D/E Ratio
for G1 Therapeutics Inc.

Provide D/A Ratio
for G1 Therapeutics Inc.

Provide Interest Coverage Ratio
for G1 Therapeutics Inc.

Provide Altman Z-Score Ratio
for G1 Therapeutics Inc.

Provide Quick Ratio
for G1 Therapeutics Inc.

Provide Current Ratio
for G1 Therapeutics Inc.

Provide Cash Ratio
for G1 Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for G1 Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for G1 Therapeutics Inc?

What is the current Free Cash Flow
of G1 Therapeutics Inc?

Financials

Balance Sheet Decomposition
G1 Therapeutics Inc

Current Assets 126.1m
Cash & Short-Term Investments 94.3m
Receivables 9.3m
Other Current Assets 22.5m
Non-Current Assets 7m
PP&E 6.8m
Other Non-Current Assets 200k
Current Liabilities 33.7m
Accounts Payable 7.3m
Accrued Liabilities 24.2m
Other Current Liabilities 2.2m
Non-Current Liabilities 56.4m
Long-Term Debt 51.2m
Other Non-Current Liabilities 5.2m
Efficiency

Earnings Waterfall
G1 Therapeutics Inc

Revenue
82.5m USD
Cost of Revenue
-7.2m USD
Gross Profit
75.3m USD
Operating Expenses
-114.8m USD
Operating Income
-39.5m USD
Other Expenses
-8.4m USD
Net Income
-48m USD

Free Cash Flow Analysis
G1 Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

GTHX Profitability Score
Profitability Due Diligence

G1 Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
28/100
Profitability
Score

G1 Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

GTHX Solvency Score
Solvency Due Diligence

G1 Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
38/100
Solvency
Score

G1 Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GTHX Price Targets Summary
G1 Therapeutics Inc

Wall Street analysts forecast GTHX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GTHX is 8.67 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

Lowest
Price Target
5.05 USD
23% Upside
Average
Price Target
8.67 USD
111% Upside
Highest
Price Target
12.6 USD
207% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GTHX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GTHX Price
G1 Therapeutics Inc

1M 1M
+19%
6M 6M
+180%
1Y 1Y
+45%
3Y 3Y
-82%
5Y 5Y
-78%
10Y 10Y
-73%
Annual Price Range
4.11
52w Low
1.12
52w High
4.88
Price Metrics
Average Annual Return -19.12%
Standard Deviation of Annual Returns 41.29%
Max Drawdown -97%
Shares Statistics
Market Capitalization 212.9m USD
Shares Outstanding 52 200 000
Percentage of Shares Shorted 5.33%

GTHX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

G1 Therapeutics Inc Logo
G1 Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

212.9m USD

Dividend Yield

0%

Description

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. The company is headquartered in Research Triangle Park, North Carolina and currently employs 148 full-time employees. The company went IPO on 2017-05-17. The firm is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The firm's lead compound COSELA (trilaciclib), is a therapy designed to help protect hematopoietic stem and progenitor cells (HSPCs) in bone marrow against chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lunger cancer (ES-SCLC). Its Lerociclib, is a differentiated clinical-stage oral CDK4/6 inhibitor for use in combination with other targeted therapies in multiple oncology indications. The firm's Rintodestrant, is a clinical-stage oral selective estrogen receptor degrader (SERD), for use as a monotherapy and in combination with CDK4/6 inhibitors, initially Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-breast cancer.

Contact

NORTH CAROLINA
RESEARCH TRIANGLE PARK
700 Park Offices Drive, Suite 200
+19192139835.0
http://www.g1therapeutics.com/

IPO

2017-05-17

Employees

148

Officers

CEO, President & Director
Mr. John E. Bailey Jr.
Chief Business Officer
Mr. Mark Avagliano
Chief Financial Officer
Mr. John W. Umstead V
Chief Operating Officer
Mr. Terry L. Murdock
Vice President of Investor Relations & Corporate Communications
Mr. William C. Roberts
General Counsel & Chief Compliance Officer
Ms. Monica R. Thomas
Show More
Vice President of Marketing
Mr. Evan Hicks M.B.A.
Chief Medical Officer
Dr. Rajesh K. Malik Ch.B., M.B., M.D.
Chief Commercial Officer
Mr. Andrew Perry
Senior Director of Investor Relations & Corporate Communications
Mr. Jeff Macdonald
Show Less

See Also

Discover More
What is the Intrinsic Value of one GTHX stock?

The intrinsic value of one GTHX stock under the Base Case scenario is 14.86 USD.

Is GTHX stock undervalued or overvalued?

Compared to the current market price of 4.11 USD, G1 Therapeutics Inc is Undervalued by 72%.